BioStratum Challenges Affidavit Asserting Pre-1994 Pyridoxamine Product
This article was originally published in The Tan Sheet
Executive Summary
Hopeful pyridoxamine drug marketer BioStratum is skeptical of an affidavit submitted to FDA by Jarrow Formulas as evidence of the pre-1994 sale of pyridoxamine in supplements
You may also be interested in...
Pyridoxamine Debate Continues; CRN Points To Ingredient’s Presence In Food
Pyridoxamine's presence in many common foods makes it exempt from 75-day premarket notification, the Council for Responsible Nutrition maintains in comments supporting the ingredient's status as a dietary supplement
Pyridoxamine Debate Continues; CRN Points To Ingredient’s Presence In Food
Pyridoxamine's presence in many common foods makes it exempt from 75-day premarket notification, the Council for Responsible Nutrition maintains in comments supporting the ingredient's status as a dietary supplement
Pyridoxamine Debate Continues; CRN Points To Ingredient’s Presence In Food
Pyridoxamine's presence in many common foods makes it exempt from 75-day premarket notification, the Council for Responsible Nutrition maintains in comments supporting the ingredient's status as a dietary supplement